1.Platelet bacterial contamination in China: a meta-analysis
Xiuyun LIAO ; Yang HUANG ; Yuan ZHANG ; Miao HE ; Zhan GAO
Chinese Journal of Blood Transfusion 2025;38(9):1272-1279
Objective: To investigate the status and influencing factors of platelet bacterial contamination in China, and to provide theoretical support for relevant policies in blood collection and transfusion institutions. Methods: A meta-analysis by systematically searching studies on platelet bacterial contamination in China published between 1998 and 2023 was conducted. Data analysis was performed using R4.4 software to combine studies that met the inclusion criteria. Results: Twenty-three studies were included after screening. The combined analysis showed that the overall contamination rate of platelets in China was 0.18% (95% CI: 0.12%-0.24%). The contamination rate of manually condensed platelets was significantly higher than that of apheresis platelet concentrates (0.28% vs 0.17%, P<0.01). No significant difference in platelet contamination rates was found between eastern and central regions (0.21% vs 0.15%, P>0.01). The contamination rate of aerobic bacteria was higher than that of anaerobic bacteria (0.11% vs 0.06%, P<0.01). Publication bias analysis indicated robust results, and sensitivity analysis showed minimal impact of excluding individual studies on the overall conclusion. Conclusion: Although the platelet contamination rate in China is generally low, significant differences exist across collection methods and regions.
2.Expert consensus on the diagnosis and treatment of cemental tear.
Ye LIANG ; Hongrui LIU ; Chengjia XIE ; Yang YU ; Jinlong SHAO ; Chunxu LV ; Wenyan KANG ; Fuhua YAN ; Yaping PAN ; Faming CHEN ; Yan XU ; Zuomin WANG ; Yao SUN ; Ang LI ; Lili CHEN ; Qingxian LUAN ; Chuanjiang ZHAO ; Zhengguo CAO ; Yi LIU ; Jiang SUN ; Zhongchen SONG ; Lei ZHAO ; Li LIN ; Peihui DING ; Weilian SUN ; Jun WANG ; Jiang LIN ; Guangxun ZHU ; Qi ZHANG ; Lijun LUO ; Jiayin DENG ; Yihuai PAN ; Jin ZHAO ; Aimei SONG ; Hongmei GUO ; Jin ZHANG ; Pingping CUI ; Song GE ; Rui ZHANG ; Xiuyun REN ; Shengbin HUANG ; Xi WEI ; Lihong QIU ; Jing DENG ; Keqing PAN ; Dandan MA ; Hongyu ZHAO ; Dong CHEN ; Liangjun ZHONG ; Gang DING ; Wu CHEN ; Quanchen XU ; Xiaoyu SUN ; Lingqian DU ; Ling LI ; Yijia WANG ; Xiaoyuan LI ; Qiang CHEN ; Hui WANG ; Zheng ZHANG ; Mengmeng LIU ; Chengfei ZHANG ; Xuedong ZHOU ; Shaohua GE
International Journal of Oral Science 2025;17(1):61-61
Cemental tear is a rare and indetectable condition unless obvious clinical signs present with the involvement of surrounding periodontal and periapical tissues. Due to its clinical manifestations similar to common dental issues, such as vertical root fracture, primary endodontic diseases, and periodontal diseases, as well as the low awareness of cemental tear for clinicians, misdiagnosis often occurs. The critical principle for cemental tear treatment is to remove torn fragments, and overlooking fragments leads to futile therapy, which could deteriorate the conditions of the affected teeth. Therefore, accurate diagnosis and subsequent appropriate interventions are vital for managing cemental tear. Novel diagnostic tools, including cone-beam computed tomography (CBCT), microscopes, and enamel matrix derivatives, have improved early detection and management, enhancing tooth retention. The implementation of standardized diagnostic criteria and treatment protocols, combined with improved clinical awareness among dental professionals, serves to mitigate risks of diagnostic errors and suboptimal therapeutic interventions. This expert consensus reviewed the epidemiology, pathogenesis, potential predisposing factors, clinical manifestations, diagnosis, differential diagnosis, treatment, and prognosis of cemental tear, aiming to provide a clinical guideline and facilitate clinicians to have a better understanding of cemental tear.
Humans
;
Dental Cementum/injuries*
;
Consensus
;
Diagnosis, Differential
;
Cone-Beam Computed Tomography
;
Tooth Fractures/therapy*
3.SFTPC Mutation-Related Interstitial Lung Disease in Infants:A Case Study and Review of Related Literature
Xiuyun ZHOU ; Liru QIU ; Min'er CAI ; Zongming YANG ; Dong XU ; Yongjian HUANG
Herald of Medicine 2025;44(12):1982-1989
To investigate the clinical characteristics,genetic mutation patterns,and therapeutic strategies of an infant with interstitial lung disease associated with a surfactant protein C(SFTPC)gene mutation,and systematic review of 188 cases of SFTPC mutation-elated childhood ILD(chILD)reported in Chinese and English literature(from database inception to December 2024)was conducted.The patient in this study was a girl aged 11 months.She presented with progressive dyspnea,hypoxemia,and severe growth retardation starting at 2 months of age.Whole-exome sequencing identified a heterozygous missense mutation in SFTPC(c.187A>G,p.K63E),inherited from her mother.Symptoms significantly improved after treatment with glucocorticoids and azithromycin,though pulmonary bullae persisted at 5-year follow-up.Literature analysis revealed that the hotspot mutation I73T was located in the linker domain,while BRICHOS domain mutations exhibited the highest genetic diversity.BRICHOS domain mutations were associated with earlier onset,whereas non-BRICHOS mutations predominantly manifested in infancy with chronic cough,hypoxemia,and growth retardation.Oxygen therapy and glucocorticoids were the most common treatments.Hydroxychloroquine was more frequently used in linker domain mutations.The overall survival rate was 84%.SFTPC mutations are a critical genetic etiology of chILD in infants.Early genetic testing combined with glucocorticoid/macrolide therapy improves prognosis,but long-term monitoring for structural lung damage(e.g.,pulmonary bullae)is essential.
4.Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis
Jinshan ZHAN ; Xiuyun XUAN ; Juanmei CAO ; Fangqi CHEN ; Changzheng HUANG
Chinese Journal of Dermatology 2025;58(8):785-788
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is a special type of dermatomyositis. It has characteristic clinical manifestations, mild myositis symptoms, and is prone to be accompanied by rapidly progressive interstitial lung disease, which indicates a poor prognosis. Its pathogenesis remains unclear, and may be related to genetic and environmental factors. This review summarizes progress in the treatment of anti-MDA5 antibody-positive dermatomyositis in recent years, in order to provide new ideas for its clinical treatment.
5.SFTPC Mutation-Related Interstitial Lung Disease in Infants:A Case Study and Review of Related Literature
Xiuyun ZHOU ; Liru QIU ; Min'er CAI ; Zongming YANG ; Dong XU ; Yongjian HUANG
Herald of Medicine 2025;44(12):1982-1989
To investigate the clinical characteristics,genetic mutation patterns,and therapeutic strategies of an infant with interstitial lung disease associated with a surfactant protein C(SFTPC)gene mutation,and systematic review of 188 cases of SFTPC mutation-elated childhood ILD(chILD)reported in Chinese and English literature(from database inception to December 2024)was conducted.The patient in this study was a girl aged 11 months.She presented with progressive dyspnea,hypoxemia,and severe growth retardation starting at 2 months of age.Whole-exome sequencing identified a heterozygous missense mutation in SFTPC(c.187A>G,p.K63E),inherited from her mother.Symptoms significantly improved after treatment with glucocorticoids and azithromycin,though pulmonary bullae persisted at 5-year follow-up.Literature analysis revealed that the hotspot mutation I73T was located in the linker domain,while BRICHOS domain mutations exhibited the highest genetic diversity.BRICHOS domain mutations were associated with earlier onset,whereas non-BRICHOS mutations predominantly manifested in infancy with chronic cough,hypoxemia,and growth retardation.Oxygen therapy and glucocorticoids were the most common treatments.Hydroxychloroquine was more frequently used in linker domain mutations.The overall survival rate was 84%.SFTPC mutations are a critical genetic etiology of chILD in infants.Early genetic testing combined with glucocorticoid/macrolide therapy improves prognosis,but long-term monitoring for structural lung damage(e.g.,pulmonary bullae)is essential.
6.Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis
Jinshan ZHAN ; Xiuyun XUAN ; Juanmei CAO ; Fangqi CHEN ; Changzheng HUANG
Chinese Journal of Dermatology 2025;58(8):785-788
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is a special type of dermatomyositis. It has characteristic clinical manifestations, mild myositis symptoms, and is prone to be accompanied by rapidly progressive interstitial lung disease, which indicates a poor prognosis. Its pathogenesis remains unclear, and may be related to genetic and environmental factors. This review summarizes progress in the treatment of anti-MDA5 antibody-positive dermatomyositis in recent years, in order to provide new ideas for its clinical treatment.
7.Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma
Xiong GAN ; Xie NAN ; Nie MIN ; Ling RONGSONG ; Yun BOKAI ; Xie JIAXIANG ; Ren LINLIN ; Huang YAQI ; Wang WENJIN ; Yi CHEN ; Zhang MING ; Xu XIUYUN ; Zhang CAIHUA ; Zou BIN ; Zhang LEITAO ; Liu XIQIANG ; Huang HONGZHANG ; Chen DEMENG ; Cao WEI ; Wang CHENG
International Journal of Oral Science 2024;16(2):251-264
Ameloblastoma is a benign tumor characterized by locally invasive phenotypes,leading to facial bone destruction and a high recurrence rate.However,the mechanisms governing tumor initiation and recurrence are poorly understood.Here,we uncovered cellular landscapes and mechanisms that underlie tumor recurrence in ameloblastoma at single-cell resolution.Our results revealed that ameloblastoma exhibits five tumor subpopulations varying with respect to immune response(IR),bone remodeling(BR),tooth development(TD),epithelial development(ED),and cell cycle(CC)signatures.Of note,we found that CC ameloblastoma cells were endowed with stemness and contributed to tumor recurrence,which was dominated by the EZH2-mediated program.Targeting EZH2 effectively eliminated CC ameloblastoma cells and inhibited tumor growth in ameloblastoma patient-derived organoids.These data described the tumor subpopulation and clarified the identity,function,and regulatory mechanism of CC ameloblastoma cells,providing a potential therapeutic target for ameloblastoma.
8.Interpretation of the European Respiratory Society Guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
Dong XU ; Liru QIU ; Xiaoping LUO ; Xiuyun ZHOU ; Yongjian HUANG
Herald of Medicine 2024;43(12):1869-1873
To improve the understanding of clinicians on the diagnostic criteria and treatment principlis of pulmonary alveolar proteinosis(PAP),which is a rare respiratory disease.European Respiratory Society published the first edition guidelines for PAP,including a systematic review of the literature and the application of the grading of recommendations,assessment,development and evaluation(GRADE)approach to assess the certainty of evidence and the strength of recommendations.Five questions of patient,intervention,comparison,outcome(PICO)and two narrative questions were developed.Recommendations and evidence-based evidence were given,including management of PAP,whole lung lavage,granulocyte-macrophage colony-stimulating factor(GM-CSF)therapy,rituximab,plasma exchange,and lung transplantation.In addition,recommendations were given for the use of GM-CSF antibody testing,bronchoalveolar lavage,and lung biopsy.This study is to interpret the main content of the guideline.
9.Research progress on ferroptosis in the treatment of oral cancer
TIAN Xiuyun ; ZHANG Pei ; HUANG Qingyang ; ZHOU Meiyun ; LUO Bin ; CHEN Xinru ; XU Jincheng
Journal of Prevention and Treatment for Stomatological Diseases 2023;31(3):217-222
Ferroptosis is a newly discovered method of programmed cell death. Current studies have shown that activation of ferroptosis-related pathways can inhibit the growth and proliferation of tumor cells and reverse their drug resistance. Oral cancer is a common malignant tumor with a high recurrence rate and high drug resistance. Inducing ferroptosis is a potential treatment strategy. There are still many uncertainties in the application of ferroptosis in the treatment of oral cancer, which need to be further explored. This article systematically introduces the mechanism of ferroptosis and its recent progress in oral cancer treatment to provide new mechanisms and methods for the clinical treatment of oral cancer. Current research shows that the mechanism of ferroptosis is mainly related to amino acid metabolism, Fe2+ metabolism, and lipid metabolism. Ferroptosis in oral cancer cells can reverse drug resistance in cancer cells and improve the activity of immune cells. New drugs, such as curcumin analogs and triptolide, can induce ferroptosis in oral cancer, and the development of nanomaterials has improved the utilization rate of drugs. Inhibiting the expression of the ferroptosis-related factors SLC7A11, NF-E2-related factor 2 (Nrf2), and ferritin heavy chain 1 (FTH1) can promote ferroptosis in oral cancer cells. It is a potential target for the clinical treatment of oral cancer, but its translation into clinical practice still needs further research.
10.Targeted muscle reinnervation: a surgical technique of human-machine interface for intelligent prosthesis.
Yao GUO ; Wei ZHAO ; Jianping HUANG ; Mingkui SHEN ; Sijing LI ; Cheng LIU ; Xiuyun SU ; Guanglin LI ; Sheng BI ; Guoxian PEI
Chinese Journal of Reparative and Reconstructive Surgery 2023;37(8):1021-1025
OBJECTIVE:
To review targeted muscle reinnervation (TMR) surgery for the construction of intelligent prosthetic human-machine interface, thus providing a new clinical intervention paradigm for the functional reconstruction of residual limbs in amputees.
METHODS:
Extensively consulted relevant literature domestically and abroad and systematically expounded the surgical requirements of intelligent prosthetics, TMR operation plan, target population, prognosis, as well as the development and future of TMR.
RESULTS:
TMR facilitates intuitive control of intelligent prostheses in amputees by reconstructing the "brain-spinal cord-peripheral nerve-skeletal muscle" neurotransmission pathway and increasing the surface electromyographic signals required for pattern recognition. TMR surgery for different purposes is suitable for different target populations.
CONCLUSION
TMR surgery has been certified abroad as a transformative technology for improving prosthetic manipulation, and is expected to become a new clinical paradigm for 2 million amputees in China.
Humans
;
Artificial Limbs
;
Muscle, Skeletal
;
Neurosurgical Procedures
;
Plastic Surgery Procedures
;
Prosthesis Implantation


Result Analysis
Print
Save
E-mail